Multidirectional in vitro and in cellulo studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer’s disease

References

• Prince M, Comas-Herrera A, Knapp M, et al. World Alzheimer report: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. 2016. Available from: http://eprints.lse.ac.uk/67858/. [accessed 20 Dec 2019].
   Google Scholar
• Knight R, Khondoker M, Magill N, et al. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord 2018;45:131–51.
   PubMed Web of Science ®Google Scholar
• Carrell RW, Lomas DA. Conformational disease. Lancet 1997;350:134–8.
   PubMed Web of Science ®Google Scholar
• van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci 2020;21:21–35.
   PubMed Web of Science ®Google Scholar
• Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement 2019;5:272–93.
   Google Scholar
• Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer’s disease. Ther Adv Neuro Diso 2013;6:19–33.
   PubMed Web of Science ®Google Scholar
• Godyń J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 2016;68:127–38.
   PubMed Web of Science ®Google Scholar
• Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 2020;27:18.
   PubMed Web of Science ®Google Scholar
• Schneider L. A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol 2020;19:111–2.
   PubMed Web of Science ®Google Scholar
• Griner SL, Seidler P, Bowler J, et al. Structure-based inhibitors of amyloid beta core suggest a common interface with tau. Elife 2019;8:e46924.
   PubMed Web of Science ®Google Scholar
• Busche MA, Wegmann S, Dujardin S, et al. Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo. Nat Neurosci 2019;22:57–64.
   PubMed Web of Science ®Google Scholar
• Bolognesi ML. Harnessing polypharmacology with medicinal chemistry. ACS Med Chem Lett 2019;10:273–5.
   PubMed Web of Science ®Google Scholar
• Albertini C, Salerno A, de Sena Murteira Pinheiro P, Bolognesi ML. From combinations to multitarget‐directed ligands: a continuum in Alzheimer’s disease polypharmacology. Med Res Rev 2020;1–28. DOI:10.1002/med.21699
   Web of Science ®Google Scholar
• Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct Target Ther 2019;4:29.
   PubMed Web of Science ®Google Scholar
• Wichur T, Więckowska A, Więckowski K, et al. 1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer’s disease. Eur J Med Chem 2020;187:111916.
   PubMed Web of Science ®Google Scholar
• Sang Z, Wang K, Shi J, et al. Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer’s disease. Eur J Med Chem 2020;187:111958.
   PubMed Web of Science ®Google Scholar
• Costa GP, Baldinotti RSM, Fronza MG, et al. Synthesis, molecular docking, and preliminary evaluation of 2-(1,2,3-triazoyl)benzaldehydes as multifunctional agents for the treatment of Alzheimer’s disease. ChemMedChem 2020;15:610–22.
   PubMed Web of Science ®Google Scholar
• Chalupova K, Korabecny J, Bartolini M, et al. Novel tacrine-tryptophan hybrids: multi-target directed ligands as potential treatment for Alzheimer’s disease. Eur J Med Chem 2019;168:491–514.
   PubMed Web of Science ®Google Scholar
• Montanari S, Mahmoud AM, Pruccoli L, et al. Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer’s disease treatment. Eur J Med Chem 2019;178:243–58.
   PubMed Web of Science ®Google Scholar
• Dolles D, Nimczick M, Scheiner M, et al. Aminobenzimidazoles and structural isomers as templates for dual-acting butyrylcholinesterase inhibitors and hCB2 R ligands to combat neurodegenerative disorders. ChemMedChem 2016;11:1270–83.
   PubMed Web of Science ®Google Scholar
• González-Naranjo P, Pérez-Macias N, Campillo NE, et al. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer’s disease. Eur J Med Chem 2014;73:56–72.
   PubMed Web of Science ®Google Scholar
• Scheiner M, Dolles D, Gunesch S, et al. Dual-acting cholinesterase-human cannabinoid receptor 2 ligands show pronounced neuroprotection in vitro and overadditive and disease-modifying neuroprotective effects in vivo. J Med Chem 2019;62:9078–102.
   PubMed Web of Science ®Google Scholar
• Malek R, Arribas RL, Palomino-Antolin A, et al. New dual small molecules for Alzheimer’s disease therapy combining histamine H3 receptor (H3R) antagonism and calcium channels blockade with additional cholinesterase inhibition. J Med Chem 2019;62:11416–22.
   PubMed Web of Science ®Google Scholar
• Bajda M, Łażewska D, Godyń J, et al. Search for new multi-target compounds against Alzheimer’s disease among histamine H3 receptor ligands. Eur J Med Chem 2020;185:111785.
   PubMed Web of Science ®Google Scholar
• Ghamari N, Dastmalchi S, Zarei O, et al. In silico and in vitro studies of two non-imidazole multiple targeting agents at histamine H3 receptors and cholinesterase enzymes. Chem Biol Drug Des 2020;95:279–90.
   PubMed Web of Science ®Google Scholar
• Li X, Wang H, Xu Y, et al. Novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of Alzheimer’s disease accompanied with depression: design, synthesis, and biological evaluation. ACS Chem Neurosci 2017;8:2708–21.
   PubMed Web of Science ®Google Scholar
• Hatat B, Yahiaoui S, Lecoutey C, et al. A novel in vivo anti-amnesic agent, specially designed to express both acetylcholinesterase (AChE) inhibitory, serotonergic subtype 4 receptor (5-HT4R) agonist and serotonergic subtype 6 receptor (5-HT6R) inverse agonist activities, with a potential interest against Alzheimer’s disease. Front Aging Neurosci 2019;11:148.
   PubMed Web of Science ®Google Scholar
• Rochais C, Lecoutey C, Hamidouche K, et al. Donecopride, a Swiss army knife with potential against Alzheimer's disease. Br J Pharmacol 2020;177:1988–2005.
   PubMed Web of Science ®Google Scholar
• Lecoutey C, Hedou D, Freret T, et al. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer’s disease treatment. Proc Natl Acad Sci USA 2014;111:3825–30.
   PubMed Web of Science ®Google Scholar
• Więckowska A, Kołaczkowski M, Bucki A, et al. Novel multi-target-directed ligands for Alzheimer’s disease: combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation. Eur J Med Chem 2016;124:63–81.
   PubMed Web of Science ®Google Scholar
• Więckowska A, Wichur T, Godyń J, et al. Novel multitarget-directed ligands aiming at symptoms and causes of Alzheimer’s disease. ACS Chem Neurosci 2018;9:1195–214.
   PubMed Web of Science ®Google Scholar
• Khoury R, Grysman N, Gold J, et al. The role of 5 HT6-receptor antagonists in Alzheimer’s disease: an update. Expert Opin Investig Drugs 2018;27:523–33.
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2014;13:1092–9.
   PubMed Web of Science ®Google Scholar
• Levine H. Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 1993;2:404–10.
   PubMed Web of Science ®Google Scholar
• Pouplana S, Espargaro A, Galdeano C, et al. Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors. Curr Med Chem 2014;21:1152–9.
   PubMed Web of Science ®Google Scholar
• Ami D, Natalello A, Lotti M, Doglia SM. Why and how protein aggregation has to be studied in vivo. Microb Cell Fact 2013;12:17.
   PubMed Web of Science ®Google Scholar
• Caballero AB, Espargaró A, Pont C, et al. Bacterial inclusion bodies for anti-amyloid drug discovery: current and future screening methods. Curr Protein Pept Sci 2019;20:563–76.
   PubMed Web of Science ®Google Scholar
• di Pietro O, Pérez-Areales FJ, Juárez-Jiménez J, et al. Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies. Eur J Med Chem 2014;84:107–17.
   PubMed Web of Science ®Google Scholar
• Espargaró A, Medina A, di Pietro O, et al. Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. Sci Rep 2016;6:23349.
   PubMed Web of Science ®Google Scholar
• Sameem B, Saeedi M, Mahdavi M, Shafiee A. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer’s disease. Eur J Med Chem 2017;128:332–45.
   PubMed Web of Science ®Google Scholar
• Zha X, Lamba D, Zhang L, et al. Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer’s disease: design, synthesis, biological evaluation, and x-ray crystallography. J Med Chem 2016;59:114–31.
   PubMed Web of Science ®Google Scholar
• Fancellu G, Chand K, Tomás D, et al. Novel tacrine-benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer’s disease. J Enzyme Inhib Med Chem 2020;35:211–26.
   PubMed Web of Science ®Google Scholar
• Lv P, Xia CL, Wang N, et al. Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation. Bioorg Med Chem 2018;26:4693–705.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Solfrizzi V, et al. BACE inhibitors in clinical development for the treatment of Alzheimer's disease. Expert Rev of Neurother 2018;18:847–57.
   PubMed Web of Science ®Google Scholar
• ben Halima S, Mishra S, Raja KMP, et al. Specific inhibition of β-secretase processing of the Alzheimer disease amyloid precursor protein. Cell Rep 2016;14:2127–41.
   PubMed Web of Science ®Google Scholar
• Stachel SJ, Coburn CA, Steele TG, et al. Structure-based design of potent and selective cell-permeable inhibitors of human β-secretase (BACE-1). J Med Chem 2004;47:6447–50.
   PubMed Web of Science ®Google Scholar
• Rueeger H, Lueoend R, Rogel O, et al. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. J Med Chem 2012;55:3364–86.
   PubMed Web of Science ®Google Scholar
• Rueeger H, Rondeau JM, McCarthy C, et al. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors. Bioorganic Med Chem Lett 2011;21:1942–7.
   PubMed Web of Science ®Google Scholar